Video
The importance of incorporating the patient’s voice when developing new treatments
Author(s):
“We need to understand what the treatment [means] to them as individuals, and how they perceive the benefit of the treatment,” says Cornelia Haag, Molkenteller, MD, PhD.
Video Player is loading.
In this video, Cornelia Haag-Molkenteller, MD, PhD, discusses the takeaways of the study, “Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).” Haag-Molkenteller is a chief medical officer at Urovant Sciences, Inc in Irvine, California.
Related Videos
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
Special Report: Tips for PCPs on evaluating prostate cancer risk
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Special Report: Tailoring prostate cancer care for older adults
Special Report: New strategies emerge for metastatic prostate cancer
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Alternative treatments and patient communication for genitourinary syndrome of menopause
Related Content
